Early clinical indicators of acute kidney injury caused by administering high-dose methotrexate therapy to juvenile pigs
暂无分享,去创建一个
[1] F. Zanaty,et al. Evaluation of kidney dysfunction in childhood cancer survivors , 2022, Pediatric Research.
[2] Shruti Gupta,et al. Conventional Chemotherapy Nephrotoxicity. , 2021, Advances in chronic kidney disease.
[3] H. Katzenstein,et al. Concurrent Imatinib Dosing With High-dose Methotrexate Leads to Acute Kidney Injury and Delayed Methotrexate Clearance in Pediatric Patients With Philadelphia Chromosome-positive B-Cell Acute Lymphoblastic Leukemia. , 2020, Journal of pediatric hematology/oncology.
[4] M. Perazella. Drug-induced acute kidney injury: diverse mechanisms of tubular injury. , 2019, Current opinion in critical care.
[5] A. Brandoni,et al. Time evolution of methotrexate‐induced kidney injury: A comparative study between different biomarkers of renal damage in rats , 2019, Clinical and experimental pharmacology & physiology.
[6] Q. Guo,et al. Identifying risk factors for high-dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia , 2019, Cancer management and research.
[7] A. Vinks,et al. Delayed methotrexate clearance in patients with acute lymphoblastic leukemia concurrently receiving dasatinib , 2019, Pediatric blood & cancer.
[8] C. Ryan,et al. Safety and efficacy of high‐dose methotrexate for osteosarcoma in adolescents compared with young adults , 2018, Cancer medicine.
[9] S. Piperno-Neumann,et al. A Pharmacokinetic and Pharmacogenetic Analysis of Osteosarcoma Patients Treated With High‐Dose Methotrexate: Data From the OS2006/Sarcoma‐09 Trial , 2018, Journal of clinical pharmacology.
[10] S. Hilsenbeck,et al. A prospective study of a simple algorithm to individually dose high-dose methotrexate for children with leukemia at risk for methotrexate toxicities , 2018, Cancer Chemotherapy and Pharmacology.
[11] Jing Tian,et al. Renal Function and Plasma Methotrexate Concentrations Predict Toxicities in Adults Receiving High-Dose Methotrexate , 2018, Medical science monitor : international medical journal of experimental and clinical research.
[12] T. Muthukumar,et al. Management of Patients with Acute Methotrexate Nephrotoxicity with High‐Dose Leucovorin , 2018, Pharmacotherapy.
[13] K. Yu,et al. Population Pharmacokinetics of High-Dose Methotrexate in Patients With Primary Central Nervous System Lymphoma. , 2018, Journal of pharmaceutical sciences.
[14] Tao-tao Liu,et al. Identification of Risk Factors in High-Dose Methotrexate-Induced Acute Kidney Injury in Childhood Acute Lymphoblastic Leukemia , 2018, Chemotherapy.
[15] C. Rioufol,et al. Delayed methotrexate elimination: Incidence, interaction with antacid drugs, and clinical consequences? , 2018, Hematological oncology.
[16] A. Rule,et al. Incorporating Cystatin C to Predict Methotrexate Elimination in Patients with CNS Lymphoma and Suspicious Renal Function , 2018, Case reports in hematology.
[17] P. Sangild,et al. Animal models of chemotherapy-induced mucositis: translational relevance and challenges. , 2018, American journal of physiology. Gastrointestinal and liver physiology.
[18] Victor G. Puelles,et al. Development of the Human Fetal Kidney from Mid to Late Gestation in Male and Female Infants , 2017, EBioMedicine.
[19] A. Bleyer,et al. Consensus Guideline for Use of Glucarpidase in Patients with High‐Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance , 2017, The oncologist.
[20] A. Rule,et al. Structural and Functional Changes in Human Kidneys with Healthy Aging. , 2017, Journal of the American Society of Nephrology : JASN.
[21] Manupat Lohitnavy,et al. A physiologically-based pharmacokinetic model of methotrexate incorporating hepatic excretion via multidrug-resistance-associated protein 2 (Mrp2) in mice, rats, dogs, and humans , 2017, 2017 39th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC).
[22] K. Schmiegelow,et al. Delayed elimination of high‐dose methotrexate and use of carboxypeptidase G2 in pediatric patients during treatment for acute lymphoblastic leukemia , 2017, Pediatric blood & cancer.
[23] M. Mrug,et al. Recovery of methotrexate-induced anuric acute kidney injury after glucarpidase therapy , 2017, SAGE open medical case reports.
[24] S. Choquet,et al. Endogenous metabolites that are substrates of organic anion transporter's (OATs) predict methotrexate clearance , 2017, Pharmacological research.
[25] M. Joannidis,et al. Acute kidney injury 2016: diagnosis and diagnostic workup , 2016, Critical Care.
[26] Z. Özdemir,et al. The frequency of hepatotoxicity and myelotoxicity in leukemic children with different high doses of methotrexate , 2016, International journal of pediatrics & adolescent medicine.
[27] A. Arany,et al. Pharmacogenetic analysis of high-dose methotrexate treatment in children with osteosarcoma , 2016, Oncotarget.
[28] C. Pui,et al. Preventing and Managing Toxicities of High-Dose Methotrexate , 2016, The oncologist.
[29] G. Phillips,et al. Evaluation of incidence and risk factors for high-dose methotrexate-induced nephrotoxicity , 2016, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
[30] L. Silverman,et al. Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus. , 2016, The Lancet. Oncology.
[31] J. Lingeman,et al. Intraluminal measurement of papillary duct urine pH, in vivo: a pilot study in the swine kidney , 2016, Urolithiasis.
[32] A. P. Garneau,et al. Acute Methotrexate-Induced Crystal Nephropathy. , 2015, The New England journal of medicine.
[33] S. Vishnubhatla,et al. Serum Creatinine Versus Plasma Methotrexate Levels to Predict Toxicities in Children Receiving High-dose Methotrexate , 2015, Pediatric hematology and oncology.
[34] T. Key,et al. Plasma concentrations and intakes of amino acids in male meat-eaters, fish-eaters, vegetarians and vegans: a cross-sectional analysis in the EPIC-Oxford cohort , 2015, European Journal of Clinical Nutrition.
[35] S. Ragab,et al. Evaluation of serum and urine fetuin-A levels in children with acute lymphoblastic leukemia during and after high-dose methotrexate therapy: Relation to toxicity , 2015, Hematology.
[36] K. Jahnukainen,et al. Assessment of renal function during high‐dose methotrexate treatment in children with acute lymphoblastic leukemia , 2014, Pediatric blood & cancer.
[37] Asha B. Pillai,et al. The Weaned Pig as a Model for Doxorubicin-Induced Mucositis , 2014, Chemotherapy.
[38] M. Perazella,et al. Crystalline-induced kidney disease: a case for urine microscopy , 2014, Clinical kidney journal.
[39] P. Wehner,et al. Extended duration of prehydration does not prevent nephrotoxicity or delayed drug elimination in high‐dose methotrexate infusions: A prospectively randomized cross‐over study , 2014, Pediatric blood & cancer.
[40] P. van Eyken,et al. “Physiological” renal regenerating medicine in VLBW preterm infants: could a dream come true? , 2012, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.
[41] M. Relling,et al. Resumption of high‐dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients , 2012, Cancer.
[42] S. Mallipattu,et al. Methotrexate in the urine. , 2011, Kidney International.
[43] S. Raimondi,et al. Shortening infusion time for high-dose methotrexate alters antileukemic effects: a randomized prospective clinical trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] Victor G Puelles,et al. Glomerular number and size variability and risk for kidney disease , 2011, Current opinion in nephrology and hypertension.
[45] A. Narla,et al. Difficulty measuring methotrexate in a patient with high-dose methotrexate-induced nephrotoxicity. , 2010, Clinical chemistry.
[46] C. Petito,et al. Safety and pharmacokinetic analysis of methotrexate administered directly into the fourth ventricle in a piglet model , 2010, Journal of Neuro-Oncology.
[47] R. Bellomo,et al. Renal plasma flow and glomerular filtration rate duringacute kidney injury in man , 2010, Renal Failure.
[48] O. Mir,et al. Hyper-alkalinization without hyper-hydration for the prevention of high-dose methotrexate acute nephrotoxicity in patients with osteosarcoma , 2010, Cancer Chemotherapy and Pharmacology.
[49] O. van Tellingen,et al. Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo , 2009, Molecular Cancer Therapeutics.
[50] H. Colom,et al. Population Pharmacokinetics of High-Dose Methotrexate After Intravenous Administration in Pediatric Patients With Osteosarcoma , 2009, Therapeutic drug monitoring.
[51] T. Salmi,et al. Long‐term follow‐up of renal function after high‐dose methotrexate treatment in children , 2008, Pediatric blood & cancer.
[52] P. Nathan,et al. Very high-dose methotrexate (33.6 g/m2) as central nervous system preventive therapy for childhood acute lymphoblastic leukemia: results of National Cancer Institute/Children's Cancer Group trials CCG-191P, CCG-134P and CCG-144P , 2006, Leukemia & lymphoma.
[53] Ş. Olgar,et al. Evaluation of kidney damage in patients with acute lymphoblastic leukemia in long‐term follow‐up: Value of renal scan , 2004, American journal of hematology.
[54] F. Zintl,et al. Influence of high-dose methotrexate therapy (HD-MTX) on glomerular and tubular kidney function. , 2003, Medical and pediatric oncology.
[55] M. Jarfelt,et al. High-dose methotrexate: on the relationship of methotrexate elimination time vs renal function and serum methotrexate levels in 1164 courses in 264 Swedish children with acute lymphoblastic leukaemia (ALL) , 2003, Cancer Chemotherapy and Pharmacology.
[56] A. Prémaud,et al. An animal model for the study of chronopharmacokinetics of drugs and application to methotrexate and vinorelbine. , 2002, Toxicology and applied pharmacology.
[57] A. Takeuchi,et al. Role of kidney-specific organic anion transporters in the urinary excretion of methotrexate. , 2001, Kidney international.
[58] B. Lindqvist,et al. Variability in methotrexate serum and cerebrospinal fluid pharmacokinetics in children with acute lymphocytic leukemia: relation to assay methodology and physiological variables. , 2000, Leukemia research.
[59] P. Adamson,et al. Dihydrofolate reductase enzyme inhibition assay for plasma methotrexate determination using a 96-well microplate reader. , 1999, Clinical chemistry.
[60] S. Garwicz,et al. High‐dose methotrexate causes short‐term suppression of growth in rabbits , 1995, Acta paediatrica.
[61] J. Borsi,et al. A comparative study on the pharmacokinetics of methotrexate in a dose range of 0.5 g to 33.6 g/m2 in children with acute lymphoblastic leukemia , 1987, Cancer.
[62] B. Chabner,et al. Dose-dependent metabolism of methotrexate in man and rhesus monkeys. , 1977, Cancer treatment reports.
[63] P. Creaven,et al. Methotrexate in Liver and Bile after Intravenous Dosage in Man , 1973, British Journal of Cancer.
[64] R. Mathôt,et al. Glucarpidase treatment for methotrexate intoxication: a case report and review of the literature. , 2018, The Netherlands journal of medicine.
[65] Xiaohui Chen,et al. Simultaneous Determination of Five Specific and Sensitive Nephrotoxicity Biomarkers in Serum and Urine Samples of Four Drug-Induced Kidney Injury Models. , 2017, Journal of chromatographic science.
[66] L. Chawla,et al. Biomarkers of renal function, which and when? , 2015, Clinica chimica acta; international journal of clinical chemistry.
[67] Yongmin Tang,et al. Serum creatinine and creatinine clearance for predicting plasma methotrexate concentrations after high-dose methotrexate chemotherapy for the treatment for childhood lymphoblastic malignancies , 2013, Cancer Chemotherapy and Pharmacology.
[68] J. Lukas,et al. Population Pharmacokinetics of High-Dose Methotrexate in Children with Acute Lymphoblastic Leukaemia , 2006, Clinical pharmacokinetics.
[69] S. Jacobsen,et al. Effect of urine pH and flow on renal clearance of methotrexate , 2004, European Journal of Clinical Pharmacology.
[70] J. Chládek,et al. [Renal excretion of methotrexate in an in vivo model in minipigs]. , 2000, Acta medica (Hradec Kralove). Supplementum.
[71] J. Borsi,et al. Pharmacokinetics and metabolism of methotrexate: an example for the use of clinical pharmacology in pediatric oncology. , 1990, Pediatric hematology and oncology.
[72] G. Koren. The Nephrotoxic Potential of Drugs and Chemicals Pharmacological Basis and Clinical Relevance , 1989, Medical toxicology and adverse drug experience.